Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Objective

Pregabalin is effective in several neuropathic pain syndromes. This trial evaluated its efficacy, safety, and tolerability for treatment of painful HIV-associated neuropathy.

Methods

This randomized, double-blind, placebo-controlled, parallel-group trial included a 2-week double-blind dose-adjustment (150-600 mg/day BID) phase, a 12-week double-blind maintenance phase, and an optional 3-month open label extension phase. The primary efficacy measure was the mean Numeric Pain Rating Scale (NPRS) score, an 11-point numeric rating scale. Secondary measures included Patient Global Impression of Change (PGIC) and sleep measurements.

Results

Baseline mean NPRS score was 6.93 for patients randomized to pregabalin (n = 151) and 6.72 for those to placebo (n = 151). Pr

SUBMITTER: Simpson DM 

PROVIDER: S-EPMC2816006 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature